The Delaware Court of Chancery has ruled that a biopharmaceutical company’s board of directors did not breach their fiduciary duties when they agreed to be acquired by Amgen Inc. for $1.16 billion.
Shareholders in Micromet Inc., a Rockville, Md., manufacturer of cancer medicines and a Delaware corporation, filed a lawsuit in late January asking the court to enjoin the firm’s acquisition by Amgen.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
